PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.792
+0.012 (1.51%)
Feb 21, 2025, 4:00 PM EST - Market closed
PAVmed Revenue
PAVmed had revenue of $996.00K in the quarter ending September 30, 2024, with 25.92% growth. This brings the company's revenue in the last twelve months to $4.03M, up 166.27% year-over-year. In the year 2023, PAVmed had annual revenue of $2.45M with 550.40% growth.
Revenue (ttm)
$4.03M
Revenue Growth
+166.27%
P/S Ratio
1.76
Revenue / Employee
$37,701
Employees
107
Market Cap
8.76M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PAVM News
- 2 days ago - Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health - PRNewsWire
- 4 days ago - PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement - PRNewsWire
- 15 days ago - Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - PRNewsWire
- 5 weeks ago - Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume - PRNewsWire
- 2 months ago - Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PRNewsWire
- 2 months ago - Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - PRNewsWire
- 2 months ago - Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - PRNewsWire
- 2 months ago - Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - PRNewsWire